Navigation Links
Growing Prevalence of Asthma is Fueling Vigorous Industry Competition for Effective, Affordable Therapies
Date:9/17/2012

NEW YORK, Sept. 17, 2012 /PRNewswire/ -- Citeline®, an Informa business, reviewed clinical trial data presented at the European Respiratory Society (ERS) conference, held September 1-5, 2012 in Vienna, Austria, noting that classical fixed-dose combination (FDC) treatments remain a focus of industry sponsors, but that novel targeted asthma drugs may also be on the horizon for persistent asthma patients.

(Logo:  http://photos.prnewswire.com/prnh/20120917/NE75453LOGO )

Respiratory drug leader GSK presented largely positive results from five pivotal Relvar (formerly Relovair) asthma trials. The results, submitted in July as part of the company's regulatory filing for asthma in the EU, demonstrated improved efficacy and safety. Citeline's Trialtrove® database monitors the development of these novel, once-daily drugs for asthma, and notes that Novartis/Merck's QMF149 program is the closest competitor behind Relvar. However, since the QMF149 program is still in phase II trials and is shifting development to the Breezhaler device, a long road remains before regulatory submission, promising Relvar a spot as the only marketed once-daily inhaled corticosteroid/long-acting beta agonist (ICS/LABA) following its approval.

"In addition to these novel therapies, Trialtrove also monitors generic FDC development, and found the majority of ongoing phase III asthma trials are for generic FDCs administered using new delivery devices, such as Chiesi's NEXThaler, Orion Pharma's Easyhaler and Vectura's Gyrohaler.  The classical FDC treatment paradigm remains highly effective for many asthma patients, and more affordable generic versions of these drugs will present strong competition for blockbusters Advair and Symbicort," states Dr. Laura Runkel, Citeline's Associate Director of Autoimmune/Inflammation.

Trialtrove data tracks biologics in development for asthma, and many are now targeting subsets of patients uncontrolled by FDCs. The most numerous candidates in ongoing trials are IL-13 antagonists, including Novartis's QBX258, AstraZeneca's tralokinumab, Sanofi/Regeneron's dupilumab, and Roche's lebrikizumab. In results presented at ERS, Roche demonstrated that lebrikizumab treatment reduced serum periostin in periostin-high subjects. The drug is currently in two large phase III studies for persistent asthma.  "Compared with other asthma drugs in the pipeline, lebrikizumab has progressed rapidly through clinical trials," notes Dr. Runkel. "Further setting lebrikizumab apart from its competitors is the fact that Roche is the only sponsor currently employing a companion diagnostic in its asthma trials." The use of a validated companion diagnostic could provide the key advantage in selecting the subset of patients most likely to benefit from IL-13 antagonism. Although companion diagnostics are rarely used in asthma trials, Citeline's Pipeline® product confirms that their use overall is on the rise and is currently tracking 82 companion diagnostics intended for approval with specific drugs.

About Citeline

Citeline provides the world's most comprehensive real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator and drug intelligence. Our data is drawn from over 20,000 unique sources and analyzed by the industry's largest team – over 250 full-time expert analysts and editors.  Our services combine both data and on-demand access to our analysts, to give you up-to-the-minute information and intelligence on which to base critical business decisions. For more information about Citeline visit www.Citeline.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Sean McIntosh
52 Vanderbilt Ave., 7th Floor
New York, NY 10017

Tel: +1.212.520.2741
Email: Sean.McIntosh@Citeline.com


'/>"/>
SOURCE Citeline
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Impact Advisors Named to Inc. 5000 List of Nations Fastest-Growing Companies
2. Kareo Recognized as the Fastest Growing Medical Office Software Company by Inc. Magazine
3. Diplomat Specialty Pharmacy Honored By Inc. Magazine as One Of The Nations Fastest-Growing Companies for Fourth Consecutive Year
4. Millennium Surgical Corp. Named to Inc. 5000 List of Fastest Growing Private Companies for The Second Year
5. Medical Alarm Concepts Begins Shipments To Europe - Company Ordering Additional Inventory To Keep Up With Growing Demand
6. Central Logic Named To 2012 Inc. 500 Fastest Growing Private Companies
7. Comprehensive Care Corporation Names Jairo Estrada Senior Management Advisor To Assist in Growing the Companys New Pharmacy Initiatives
8. Vesta Inc. Opens Frankfurt Office to Increase Service to Their Growing Medical Device Contracting Business Overseas
9. E-Prescribing Trend is Growing; Pennsylvania Ranks 11th in Nation
10. CPhI China 2012 Breaks Attendance Records in Growing Pharma Market
11. RD Legal Funding Provides Immediate Settlement Financing to Growing Number of Yaz and Yasmin Plaintiffs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , February 24, 2017 Following ... Israel , s AMAR is a ... 250 M w ound care market in ... BST for inclusion in the National Health ... system   E-QURE Corp. (OTCQB: EQUR), a ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Hemophilia Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Hemophilia market? What are the unit ...
(Date:2/24/2017)... 2017 Medical information groups within the ... self-service capabilities to manage inquiries from external stakeholders ... New research from consulting leader Best Practices, LLC ... website portals where HCPs can sign on and ... many findings to emerge from the new study ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health ... British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition ... Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol treatment ...
(Date:2/26/2017)... TROY, MICHIGAN (PRWEB) , ... February 25, 2017 , ... ... leader Kim Jong-un, heightened awareness and concern over nerve agents and the deadly use ... on the human nervous system and how even small doses can be lethal. , ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby Products, an innovative ... it would be offering some it’s exclusive product line to the public through ... unique baby clothing/feeding products, will team up with AMAZON to distribute a limited ...
(Date:2/26/2017)... ... 26, 2017 , ... Functional imaging data supports improved cognition ... released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. , ... in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao et ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... on tooth replacement options at his office, Antoine Dental Center. Currently, patients can ... $18,499. Some restrictions may apply, but patients can learn more about these offers ...
Breaking Medicine News(10 mins):